ABcann Global Corporation (TSXV:ABCN) estimates its revenues to grow multifold through 2021, reaching $500 million from less than $1.0 million run rate
SmallCapPower | April 20, 2018: ABcann Global Corporation (TSXV:ABCN) is a junior cannabis player holding a niche in cultivation technologies that deliver higher yields and consistent quality. ABcann is planning aggressive expansion of its flagship facility in Napanee, Ontario, with production targets of over 30,000 kgs annually by 2019.
For Our Complete Coverage Of Canadian Marijuana Stocks Click Here
The correction in cannabis stocks over the past two months has had a devastating effect on junior cannabis players such as ABcann Global. From the high of $3.85 on January 25, 2018, the share price of ABcann has fallen 59% to its recent price of $1.59. As the Company continues its expansion activities over the next two years, increasing its production and revenues, its stock price could rebound. ABcann Global estimates its revenues to grow multifold through 2021, reaching $500 million from less than $1.0 million run rate, as of September 30, 2017. An important catalyst for the stock would be the completion of its 30,000 sq. ft Vanluven facility in Napanee by mid-2018, for an output of 1,400 kgs annually, that would target both the medical and adult-use markets.
Investment thesis
- Proprietary growing techniques deliver industry-leading yields
- Aggressive expansion and product development plans
- Strong liquidity to support expansion activities
Proprietary cultivation techniques
One of the key differentiators of ABcann Global, amongst several emerging cannabis producers, is its proprietary growing techniques that optimize costs, while delivering quality products. The technology centred on its specially designed, environmentally-controlled growing chambers, are estimated to produce quality pharmaceutical-grade cannabis products, with industry-leading yields of 250 grams/sq. ft/year that are expected to reach 400 grams/sq. ft/year, compared to the perceived industry average of ~200 grams/sq. ft/year.
Proprietary Cultivation Technology
Source: Company presentation
Aggressive expansion and product development plans
ABcann Global is planning to complete its Phase I 30,000 sq. ft Vanluven facility in Napanee by mid-2018 that is expected to produce about 1,400 kgs per year. The Phase II expansion will involve construction of a 150,000 sq ft Kimmett Facility in Napanee for an output of 17,000 kgs annually. A seasonal greenhouse at Napanee with 320,000 sq ft is anticipated to add another 14,000 kgs per year, taking the total production capacity in Napanee to over 30,000 kgs annually.
Expanding Capacity to 32 Tons in Napanee
Concurrently, ABcann Global plans to focus on branding and product innovation in the medical and adult-use sectors. Starting with dried cannabis, which are already available for patients, the Company plans to produce cannabis oils, caps and sprays in H1 2018, followed by transdermal and sublingual tabs in H2 2018. In 2019, additional products are planned, which includes soft gels, edibles and beverages.
Product Development Roadmap
Source: Company presentation
ABcann Global is also planning international expansion across select jurisdictions. In January 2018, the Company’s Australian subsidiary ABcann Australia Pty Ltd. received an Australian import license, with initial shipments expected in Q3 2018. The other key international market for ABcann is Germany and it expects its distribution license in Q4 2018.
Foothold established in Canada, Germany, Australia and Israel
Source: Company presentation
Key forthcoming events in International expansion
Source: Company presentation
Scaling up clinic business post acquisition of Harvest Medicine
ABcann Global acquired the cannabis clinic business ‘Harvest Medicine Inc.,’ a cannabis discovery center and clinic, in February 2018. Harvest Medicine currently has over ~10,000 active patients with a monthly new patient acquisition rate of 1,300 from a single location. ABcann plans to add four new locations nationwide and expand the highly-rated initial location to add over 15,000 active patients per year.
Scaling-Up Harvest Medicine – Four New Locations Planned
Source: Company presentation
Strong liquidity to support expansion activities
With the closing of an oversubscribed financing of $75 million in February 2018, ABcann has cash of over $100 million, possibly sufficient to fund its expansion and production development plans through 2019, including the 150,000 sq. ft Kimmett Facility, which is expected to require $50 million in capex.
Outlook and valuation
The correction in cannabis stocks over the past two months has had a devastating effect on junior cannabis players such as ABcann Global. From the high of $3.85 on January 25, 2018, the share price of ABcann has fallen 59% to its recent price of $1.59. As the Company continues its expansion activities over the next two years, increasing its production and revenues, its stock price could rebound.
ABcann Revenue Forecasts through 2021
Source: Company presentation
Disclosure: Neither the author nor his family own shares in the company mentioned above.
To read our full disclosure, please click on the button below:
